Is MDGEF or NOBL a better dividend investment in 2026?

MDGEF currently yields 77.22% with a 5% 5-year dividend growth rate. NOBL yields 4.00% with 5% growth. The better choice depends on your goal: MDGEF offers higher current income.

What is the dividend yield difference between MDGEF and NOBL?

MDGEF has a forward dividend yield of 77.22% ($2.00/share annually). NOBL yields 4.00% ($2.00/share annually). The yield gap is 73.22 percentage points.

Home › Compare › MDGEF vs NOBL

MDGEF vs NOBL: Dividend Comparison 2026

MDGEF yields 77.22% · NOBL yields 4.00%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MDGEF wins by $1.44M in total portfolio value

INVESTMENT

TIME HORIZON10 years

MDGEF

● Live price

77.22%

Share price

$2.59

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1.46M

Annual income

$412,841.82

Full MDGEF calculator →

NOBL

● Live price

4.00%

Share price

$50.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.0K

Annual income

$899.19

Full NOBL calculator →

Portfolio growth — MDGEF vs NOBL

📍 MDGEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MDGEF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MDGEF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MDGEF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDGEF

Annual income on $10K today (after 15% tax)

$6,563.71/yr

After 10yr DRIP, annual income (after tax)

$350,915.55/yr

NOBL

Annual income on $10K today (after 15% tax)

$340.00/yr

After 10yr DRIP, annual income (after tax)

$764.31/yr

At 15% tax rate, MDGEF beats the other by $350,151.24/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDGEF + NOBL for your $10,000?

MDGEF: 50%NOBL: 50%

100% NOBL50/50100% MDGEF

Portfolio after 10yr

$746.3K

Annual income

$206,870.51/yr

Blended yield

27.72%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MDGEF right now

MDGEF

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-23.8

Piotroski

2/9

NOBL

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDGEF buys

NOBL buys

No recent congressional trades found for MDGEF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMDGEFNOBL

Forward yield	77.22% ✓	4.00%
Annual dividend / share	$2.00	$2.00
Payout ratio	50%	50%
1-year div growth	0%	5% ✓
5-year div CAGR	0%	5% ✓
Portfolio after 10y	$1.46M	$28.0K ✓
Annual income after 10y	$412,841.82 ✓	$899.19
Total dividends collected	$1.27M	$6.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: MDGEF vs NOBL ($10,000, DRIP)

Year	MDGEF Portfolio	MDGEF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$18,422	$7,722.01	$11,120	$420.00	+$7.3K → MDGEF
2	$33,006	$13,294.85	$12,357	$458.31	+$20.6K → MDGEF
3	$57,579	$22,261.83	$13,721	$499.76	+$43.9K → MDGEF
4	$97,904	$36,294.48	$15,227	$544.58	+$82.7K → MDGEF
5	$162,433	$57,675.85	$16,885	$593.02	+$145.5K → MDGEF
6	$263,233	$89,430.36	$18,713	$645.34	+$244.5K → MDGEF
7	$417,107	$135,446.75	$20,724	$701.81	+$396.4K → MDGEF
8	$646,885	$200,581.45	$22,938	$762.73	+$623.9K → MDGEF
9	$982,896	$290,728.34	$25,372	$828.41	+$957.5K → MDGEF
10	$1,464,540	$412,841.82	$28,047	$899.19	+$1.44M → MDGEF

MDGEF vs NOBL: Complete Analysis 2026

MDGEF — Stock

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Full MDGEF Calculator →

NOBL — ETF

NOBL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in NOBL shares.

Full NOBL Calculator →

📬

Get this MDGEF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDGEF vs SCHD MDGEF vs JEPI MDGEF vs O MDGEF vs KO MDGEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.